Moderna COVID-19 Vaccine overview and safety

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Aug. 19, 2021
  
  NOTICE: HHS announced a plan to begin offering COVID-19 vaccine booster shots this fall. CDC’s independent advisory committee, the Advisory Committee on Immunization Practices, will continue to meet and discuss data on the evolution of the pandemic and the use of COVID-19 vaccines. ACIP will make further recommendations on the use of boosters for the public after a thorough review of the evidence.
  
  Cases of myocarditis and pericarditis in adolescents and young adults have been reported more often after getting the second dose than after the first dose of one of the two mRNA COVID-19 vaccines, Pfizer-BioNTech or Moderna. These reports are rare and the known and potential benefits of COVID-19 vaccination outweigh the known and potential risks, including the possible risk of myocarditis or pericarditis.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Viral Vaccines
• Document Type:
  Webpage
• Name as Subject:
  Moderna COVID-19 vaccine
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:3685879653c788c218ee6f9ff87f46a145f354cf0dec606ec679c5a6beec8d44
• Download URL:
  https://stacks.cdc.gov/view/cdc/109018/cdc_109018_DS1.pdf
• File Type:
  [PDF - 516.88 KB ]